Regeneron Pharmaceuticals (NSDQ:REGN) said today that the FDA plans to review the supplemental biologics license application for Regeneron’s Eylea aflibercept injection for the treatment of diabetic retinopathy.
The U.S. agency plans to make a decision about the blockbuster drug by May 13, 2019.
Get the full story at our sister site, Drug Delivery Business News.
The post FDA to review Regeneron’s Eylea for diabetic retinopathy appeared first on MassDevice.
from MassDevice https://ift.tt/2Mpltyt
Cap comentari:
Publica un comentari a l'entrada